Aisha Zaidi, Hematologist and Oncologist at Virginia Cancer Institute, shared a post on LinkedIn:
“Menopause and Cancer Survivorship: What the HRT Update Really Means
The recent removal of the ‘black box’ warning from menopause-related HRT products has raised understandable questions — especially for breast cancer survivors.
Let’s be clear:
- ASCO and leading oncology societies still advise against systemic HRT for anyone with a history of breast cancer, particularly hormone-receptor–positive disease.
- Local low-dose vaginal estrogen may be considered, but only after non-hormonal options fail and always under specialist guidance.
- Personalized survivorship care remains essential.
Clarity over confusion
Safety over assumptions
Personalized pathways over generic advice.”
You Can Also Read: Hormonal Replacement Therapy in Cancer Survivors: Safety, Benefits, and Clinical Guidelines
